{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-030845","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2024-10-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.569275+00:00","generated_at":"2026-05-30T17:41:15.526376+00:00","sec_items":["7.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cassava Sciences agrees to $40M SEC settlement; ReTHINK Phase 3 top-line due by year end","bullets":["Agreed to pay $40M civil penalty to SEC for negligent disclosures related to Phase 2b study; DOJ not expected to charge company.","ReTHINK Phase 3 (804 patients, 77 sites) completed last patient visit; top-line results expected before year end 2024.","ReFOCUS Phase 3 (1,125 patients) results expected mid-2025; DSMB recommended program continuation without modification.","Separated CEO and Board Chair roles as part of governance enhancements; Rick Barry remains CEO.","Nearly 90% of Phase 3 patients elected open-label extension trial; Phase 2 data showed mild patients stable over 24 months on simufilam."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-030845","json":"https://secwatch.observer/filing/0001437749-24-030845.json","markdown":"https://secwatch.observer/filing/0001437749-24-030845.md","text":"https://secwatch.observer/filing/0001437749-24-030845.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000143774924030845/0001437749-24-030845-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000143774924030845/sava20241007_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T17:41:15.526376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}